

Valery V. Tkachev,^{a*}
Klaus-Jürgen Schaper,^b
Nadezda N. Strakhova^c and
Vladimir P. Kazachenko^c^aLaboratory of Structural Chemistry, Institute of Problems of Chemical Physics, Russian Academy of Sciences, 142432 Chernogolovka, Russian Federation, ^bResearch Center Borstel, Leibniz Center for Medicine and Biosciences, D-23845 Borstel, Germany, and ^cLaboratory of Computer-Aided Molecular Design, Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russian Federation



Correspondence e-mail: germanper@yandex.ru

Key indicators

Single-crystal X-ray study
 $T = 293$ K
Mean $\sigma(\text{C}-\text{C}) = 0.007$ Å
 R factor = 0.049
 wR factor = 0.103
Data-to-parameter ratio = 12.1For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.*N*-(2,3-Dichlorophenyl)benzenesulfonamideIn the crystal structure of the title compound, $\text{C}_{12}\text{H}_9\text{Cl}_2\text{NO}_2\text{S}$, the dihedral angle between the two benzene rings is $54.8(2)^\circ$. Intermolecular $\text{N}-\text{H}\cdots\text{O}$ hydrogen bonds lead to infinite helices along the b axis.Received 18 May 2006
Accepted 24 May 2006

Comment

Sulfanyls and sulfonamides are drugs used for the treatment of infections, some fungal and some protozoal. Other therapeutic applications are as diuretic and hypoglycaemic agents. Furthermore, the compounds are very interesting from a fundamental point of view, e.g. for studying the relationship between van der Waals interactions and hydrogen-bond topology in the formation of crystal structures.

A view of the title compound, (I), with the atomic numbering is presented in Fig. 1. The conformation can be characterized in the following way. The torsion angle $\text{O}1-\text{S}1-\text{C}1-\text{C}2$, defining the orientation of the SO_2 group relative to ring Ph1 (atoms $\text{C}1-\text{C}6$), is $7.4(4)^\circ$. The benzene rings are rotated relative to each other by $54.8(2)^\circ$. The torsion angle $\text{N}1-\text{S}1-\text{C}1-\text{C}2$ is $-106.8(3)^\circ$, whereas the torsion angle $\text{S}1-\text{N}1-\text{C}7-\text{C}12$, defining the orientation of the SO_2 group with respect to ring Ph2 ($\text{C}7-\text{C}12$), is $-63.8(4)^\circ$.**Figure 1**
A view of the molecular structure, showing the atomic numbering scheme. Displacement ellipsoids are drawn at the 20% probability level.

Intermolecular N—H...O hydrogen bonds (dashed lines in Fig. 2) result in infinite helices along the *b* axis. Numeric details are given in Table 1. The hydrogen-bond network can be described by the graph-set *C4* (Etter, 1990). The packing of molecules in the crystal structure is also illustrated in Fig. 3.

Experimental

The chemical synthesis of the compound has been performed by analogy with procedures described in papers by Crosley *et al.* (1940), Anderson *et al.* (1942) and Gutsche *et al.* (1974), by reaction of a substituted aromatic amine (here 2,3-dichloroaniline) with benzene-sulfonyl chloride in dry pyridine, followed by precipitation of the end product by pouring the reaction mixture into water and by acidification to pH 5. Single crystals of the title compound were grown from a water–ethanol solution (20:1) by vapour diffusion. (Guillory, 1999).

Crystal data

$C_{12}H_9Cl_2NO_2S$	$Z = 4$
$M_r = 302.16$	$D_x = 1.524 \text{ Mg m}^{-3}$
Monoclinic, $P2_1/c$	Mo $K\alpha$ radiation
$a = 8.466 (1) \text{ \AA}$	$\mu = 0.64 \text{ mm}^{-1}$
$b = 9.805 (1) \text{ \AA}$	$T = 293 (2) \text{ K}$
$c = 15.876 (2) \text{ \AA}$	Prism, colourless
$\beta = 92.10 (1)^\circ$	$0.28 \times 0.2 \times 0.11 \text{ mm}$
$V = 1317.0 (3) \text{ \AA}^3$	

Data collection

Bruker P4 diffractometer	$R_{\text{int}} = 0.042$
ω - 2θ scans	$\theta_{\text{max}} = 25.0^\circ$
Absorption correction: none	3 standard reflections
2824 measured reflections	frequency: 120 min
2022 independent reflections	intensity decay: none
1152 reflections with $I > 2\sigma(I)$	

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.034P)^2]$
$R[F^2 > 2\sigma(F^2)] = 0.049$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.103$	$(\Delta/\sigma)_{\text{max}} = 0.001$
$S = 1.00$	$\Delta\rho_{\text{max}} = 0.24 \text{ e \AA}^{-3}$
2022 reflections	$\Delta\rho_{\text{min}} = -0.21 \text{ e \AA}^{-3}$
167 parameters	Extinction correction: <i>SHELXL97</i>
H atoms treated by a mixture of independent and constrained refinement	Extinction coefficient: 0.0030 (9)

Table 1

Hydrogen-bond geometry (\AA , $^\circ$).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$N1-H1\cdots O2^i$	0.76 (4)	2.30 (4)	3.039 (4)	166 (4)

Symmetry code: (i) $-x + 2, y - \frac{1}{2}, -z + \frac{3}{2}$.

C-bound H atoms were positioned geometrically and refined as riding, with $C-H = 0.93 \text{ \AA}$; $U_{\text{iso}}(\text{H})$ values were set equal to $1.2U_{\text{eq}}(\text{C})$. The coordinates of the N-bound H atom were determined by an optimization procedure and refined freely [$N-H = 0.76 (4) \text{ \AA}$].

Data collection: *CAD-4-PC Software* (Enraf–Nonius, 1989); cell refinement: *CELDIM* in *CAD-4-PC Software*; data reduction: *XCAD4* (McArdle & Higgins, 1995); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997a); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997a); molecular graphics: *SHELXTL* (Sheldrick, 1997b); software used to prepare material for publication: *SHELXTL*.




Figure 2

Projection of the molecular packing along the *a* axis. Hydrogen bonds are indicated by dashed lines.




Figure 3

Projection of the molecular packing along the *b* axis.

This work was supported by ISTC (project No. 0888).

References

- Anderson, G. W., Faith, H. E., Marson, H. W., Winnek, P. S. & Roblin, R. O. (1942). *J. Am. Chem. Soc.* **64**, 2902–2905.
- Crosley, M. L., Northey, E. H. & Hultquist, M. E. (1940). *J. Am. Chem. Soc.* **62**, 372–374.
- Enraf–Nonius (1989). *CAD-4 Software*. Version 5.0. Enraf–Nonius, Delft, The Netherlands.
- Etter, M. C. (1990). *Acc. Chem. Res.* **23**, 120–126.
- Guillory, J. K. (1999). *Polymorphism in Pharmaceutical Solids*, edited by H. G. Brittain, pp. 183–226. New York: Marcel Dekker Inc.
- Gutsche, K., Schröder, E., Rufer, C. & Loge, O. (1974). *Arzneim. Forsch. (Drug Res.)*, **24**, 1028–1039.
- McArdle, P. & Higgins, T. (1995). *XCAD*. National University of Ireland, Galway, Ireland.
- Sheldrick, G. M. (1997a). *SHELXL97* and *SHELXS97*. University of Göttingen, Germany.
- Sheldrick, G. M. (1997b). *SHELXTL*. Bruker AXS Inc., Madison, Wisconsin, USA.